Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Nonopsonic activation of neutrophils by Helicobacter pylori is inhibited by rebamipide.

Danielsson D, Jurstrand M.

Dig Dis Sci. 1998 Sep;43(9 Suppl):167S-173S.

PMID:
9753245
2.

Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants.

Suzuki M, Miura S, Mori M, Kai A, Suzuki H, Fukumura D, Suematsu M, Tsuchiya M.

Gut. 1994 Oct;35(10):1375-8.

3.

Rebamipide protects against activation of neutrophils by Helicobacter pylori.

Yoshida N, Yoshikawa T, Iinuma S, Arai M, Takenaka S, Sakamoto K, Miyajima T, Nakamura Y, Yagi N, Naito Y, Mukai F, Kondo M.

Dig Dis Sci. 1996 Jun;41(6):1139-44.

PMID:
8654144
4.

Characteristics of attenuating effects of rebamipide, an anti-ulcer agent, on oxidative burst of human neutrophils.

Shimoyama T, Fukuda S, Liu Q, Fukuda Y, Nakaji S, Sugawara K.

J Pharmacol Sci. 2003 Feb;91(2):153-7.

5.

Effects of rebamipide on gastric cell damage by Helicobacter pylori-stimulated human neutrophils.

Han BG, Kim HS, Rhee KH, Han HS, Chung MH.

Pharmacol Res. 1995 Oct;32(4):201-7.

PMID:
8866835
6.
8.

In vitro studies indicating antioxidative properties of rebamipide.

Iinuma S, Naito Y, Yoshikawa T, Takahashi S, Takemura T, Yoshida N, Kondo M.

Dig Dis Sci. 1998 Sep;43(9 Suppl):35S-39S. Review.

PMID:
9753224
9.

Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils.

Nagano C, Azuma A, Ishiyama H, Sekiguchi K, Imagawa K, Kikuchi M.

J Pharmacol Exp Ther. 2001 Apr;297(1):388-94.

PMID:
11259567
11.

Inhibition of nonopsonic Helicobacter pylori-induced activation of human neutrophils by sialylated oligosaccharides.

Teneberg S, Jurstrand M, Karlsson KA, Danielsson D.

Glycobiology. 2000 Nov;10(11):1171-81.

PMID:
11087709
12.

Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells.

Hayashi S, Sugiyama T, Amano K, Isogai H, Isogai E, Aihara M, Kikuchi M, Asaka M, Yokota K, Oguma K, Fujii N, Hirai Y.

Antimicrob Agents Chemother. 1998 Aug;42(8):1895-9.

13.

Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines.

Aihara M, Azuma A, Takizawa H, Tsuchimoto D, Funakoshi Y, Shindo Y, Ohmoto Y, Imagawa K, Kikuchi M, Mukaida N, Matsushima K.

Dig Dis Sci. 1998 Sep;43(9 Suppl):174S-180S.

PMID:
9753246
14.

Rebamipide inhibits ceramide-induced interleukin-8 production in Kato III human gastric cancer cells.

Masamune A, Yoshida M, Sakai Y, Shimosegawa T.

J Pharmacol Exp Ther. 2001 Aug;298(2):485-92.

PMID:
11454909
15.

Rebamipide prevents delay of acetic acid-induced gastric ulcer healing caused by Helicobacter pylori infection in Mongolian gerbils.

Watanabe T, Higuchi K, Hamaguchi M, Tanigawa T, Wada R, Tominaga K, Fujiwara Y, Arakawa T.

Dig Dis Sci. 2002 Jul;47(7):1582-9.

PMID:
12141820
16.

The effect of rebamipide on Helicobacter pylori extract-mediated changes of gene expression in gastric epithelial cells.

Yoshida N, Ishikawa T, Ichiishi E, Yoshida Y, Hanashiro K, Kuchide M, Uchiyama K, Kokura S, Ichikawa H, Naito Y, Yamamura Y, Okanoue T, Yoshikawa T.

Aliment Pharmacol Ther. 2003 Jul;18 Suppl 1:63-75.

17.
18.

Combined effect of rebamipide and ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells.

Hayashi S, Sugiyama T, Yokota K, Isogai H, Isogai E, Shimomura H, Oguma K, Asaka M, Hirai Y.

Microbiol Immunol. 2000;44(7):557-62.

20.

Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing.

Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A.

Dig Dis Sci. 1998 Sep;43(9 Suppl):5S-13S. Review.

PMID:
9753220

Supplemental Content

Support Center